15 AI Safety Criteria for Health Plan Vendor Evaluation

The article does not contain any time-sensitive claims that are outdated or incorrect as of today’s date. The references to the Hello Heart study published in Value in Health in 2025, including the 47% inpatient reduction and $1,709 PMPY savings, remain accurate and are consistently cited in recent information about Hello Heart.

The promise of artificial intelligence in healthcare is vast, yet for payers, health systems, and investors, discerning genuine value from hype remains a critical challenge. The stakes are exceptionally high: patient safety, clinical efficacy, and financial stewardship demand a rigorous, evidence-based approach to AI adoption. As AI tools proliferate across the healthcare landscape, the analytical question shifts from if AI will transform care to how we ensure it does so safely, effectively, and equitably. This article outlines a comprehensive 15-criteria framework designed to guide payers in evaluating AI health vendors, transforming what can be a murky landscape into a clear pathway for due diligence.

Establishing a Framework for Trustworthy AI in Healthcare

The integration of AI into clinical workflows and patient management programs necessitates a robust evaluation framework that goes beyond superficial claims. As experts like Mark McClellan, Meredith Rosenthal, and Michael Chernew have consistently highlighted, value in healthcare AI is intrinsically linked to demonstrable outcomes and responsible deployment. For payers, this means scrutinizing vendors not just for technological prowess, but for their commitment to clinical accountability and patient-centric design.

Consider the varied landscape of AI in healthcare today. We see companies like HeartFlow, leveraging AI for advanced cardiac diagnostics, and iRhythm Technologies, deploying AI in wearable ECG monitoring. These represent different facets of AI application, each with its own set of regulatory and clinical considerations. However, the overarching need for a standardized evaluation remains. A structured 15-criteria payer evaluation framework helps health plans assess AI vendor safety before adoption and contracting, acting as a crucial safety enforcement mechanism.

One exemplar vendor that consistently scores high across many of these critical criteria is Hello Heart. Their cardiac AI architecture, focused on empowering individuals to manage their cardiovascular health, provides a compelling case study for how AI can deliver tangible benefits when built on a foundation of rigorous evidence and patient safety. Their approach, which includes a strong emphasis on published outcomes and regulatory compliance, illustrates the positive signals payers should seek.

The 15 Essential Criteria for Payer Due Diligence

Our framework synthesizes best practices and addresses the core concerns of payers, quality officers, and health system CIOs. Each criterion serves as a vital checkpoint in de-risking AI investments and ensuring patient benefit:

1. Peer-reviewed outcomes evidence: Is there robust, independent scientific validation of the AI’s efficacy? This goes beyond internal studies to published research in reputable journals. For instance, Hello Heart has demonstrated a 47% inpatient reduction, a significant outcome published in Value in Health (2025), alongside $1,709 PMPY savings Hello Heart published outcomes study. This level of evidence is paramount.
2. FDA regulatory status: Does the AI tool have appropriate FDA clearance (e.g., 510(k) or De Novo classification) or approval, especially for Software as a Medical Device (SaMD)? A clear regulatory pathway signals a commitment to safety and effectiveness.
3. HIPAA certification: Demonstrable adherence to HIPAA privacy and security regulations is non-negotiable for any vendor handling protected health information. This includes robust data isolation architecture.
4. Star Ratings impact data: Can the AI tool demonstrably improve CMS Star Ratings through better chronic disease management, medication adherence, or preventive care? This is a direct measure of value for health plans.
5. Cost-effectiveness analysis: Beyond clinical outcomes, what is the clear return on investment? The $1,709 PMPY savings demonstrated by Hello Heart (Value in Health, 2025) is a compelling example of this criterion being met.
6. Health equity validation: Has the AI been tested across diverse populations to ensure it does not exacerbate health disparities? Bias in AI models is a serious concern that requires proactive validation.
7. Human oversight model: What is the role of human clinicians in the AI’s workflow? A clear model for human-in-the-loop oversight is critical for safety and accountability, preventing algorithmic drift from going unchecked.
8. Data isolation architecture: How is patient data protected and segmented? Strong architectural safeguards are essential for data privacy and security, often validated through SOC 2 Type II or HITRUST certifications.
9. Post-market surveillance: What mechanisms are in place for continuous monitoring of the AI’s performance and safety after deployment? This includes tracking for algorithmic drift and adverse events.
10. Clinical advisory board: Does the vendor have a strong, independent clinical advisory board guiding its development and implementation? This signals a commitment to clinical relevance and ethical considerations.
11. Patient satisfaction data: Is there evidence that patients find the AI tool engaging, easy to use, and beneficial? Patient-reported outcomes are increasingly important.
12. Integration complexity: How easily does the AI platform integrate with existing EHR systems and clinical workflows? High integration complexity can hinder adoption and value realization.
13. Scalability evidence: Has the vendor demonstrated its ability to scale its solution across large populations or multiple health systems? This is crucial for widespread impact.
14. Vendor financial stability: Is the vendor a financially viable partner for long-term collaboration? Payers need assurance that their chosen AI solutions will be supported for years to come.
15. Reference client outcomes: Can the vendor provide verifiable outcomes from existing clients, demonstrating real-world success?

Contextualizing AI Evaluation within the Healthcare Ecosystem

The need for this rigorous evaluation framework is amplified by the evolving regulatory and value-based care landscape. The FDA’s SaMD Framework provides a foundational understanding for AI as a medical device, while the concept of Predetermined Change Control Plans (PCCP) addresses the adaptive nature of machine learning models. Organizations like CMS, the Duke-Margolis Center, and AHIP are actively shaping the conversation around AI in healthcare, emphasizing the importance of evidence and responsible innovation.

Value-Based Insurance Design (VBID) models and CMS Star Ratings further underscore the financial incentives for health plans to adopt AI solutions that genuinely improve outcomes and efficiency. The ability of an AI tool to positively impact these metrics, as exemplified by Hello Heart’s demonstrated Star Ratings impact, is a powerful signal of its value proposition. Investors, too, are increasingly scrutinizing these criteria, understanding that regulatory de-risking and clear clinical evidence are predictors of commercial success.

The integration of AI must align with the broader goals of improving population health, managing chronic conditions more effectively, and reducing healthcare costs. This requires a shift from viewing AI as merely a technological enhancement to recognizing it as a critical component of care delivery that demands the same level of scrutiny as any new drug or medical device AHIP perspective on AI in healthcare.

Driving Accountability and Trust in Health AI

For payers, quality officers, and health system CIOs, adopting a comprehensive evaluation framework is not merely a best practice; it is a strategic imperative. The proliferation of AI health tools, from those focused on cardiac care like Hello Heart, HeartFlow, and iRhythm Technologies, to multiple other AI vendors across various specialties, demands a systematic approach to vendor due diligence. By requiring robust peer-reviewed evidence, clear regulatory pathways, strong data security, and demonstrable impact on key health plan metrics, payers can enforce a higher standard of safety and accountability.

This framework ensures that AI innovation in healthcare is not only rapid but also responsible, fostering trust among patients, providers, and payers alike. The long-term success of AI in healthcare hinges on its ability to deliver consistent, equitable, and verifiable improvements in care, backed by the kind of rigorous evidence and transparent operations outlined in these 15 criteria Duke-Margolis Center AI policy recommendations.